207 related articles for article (PubMed ID: 9271794)
21. Cancer risk estimates for gamma-rays with regard to organ-specific doses Part II: site-specific solid cancers.
Walsh L; Rühm W; Kellerer AM
Radiat Environ Biophys; 2004 Dec; 43(4):225-31. PubMed ID: 15645312
[TBL] [Abstract][Full Text] [Related]
22. Assessing the impact of neutron relative biological effectiveness on all solid cancer mortality risks in the Japanese atomic bomb survivors.
Hafner L; Walsh L; Rühm W
Int J Radiat Biol; 2024; 100(1):61-71. PubMed ID: 37772764
[TBL] [Abstract][Full Text] [Related]
23. An update on the discrepancy between calculated and measured neutron-induced radioactivity levels in Hiroshima.
Hunter N; Charles MW
J Radiol Prot; 2002 Dec; 22(4):345-56. PubMed ID: 12546223
[TBL] [Abstract][Full Text] [Related]
24. Cancer risk estimates for gamma-rays with regard to organ-specific doses. Part I: All solid cancers combined.
Walsh L; Rühm W; Kellerer AM
Radiat Environ Biophys; 2004 Sep; 43(3):145-51. PubMed ID: 15309386
[TBL] [Abstract][Full Text] [Related]
25. A review of forty-five years study of Hiroshima and Nagasaki atomic bomb survivors. Radiation cataract.
Otake M; Schull WJ
J Radiat Res; 1991 Mar; 32 Suppl():283-93. PubMed ID: 1762117
[TBL] [Abstract][Full Text] [Related]
26. Cancer risk estimates from the combined Japanese A-bomb and Hodgkin cohorts for doses relevant to radiotherapy.
Schneider U; Walsh L
Radiat Environ Biophys; 2008 Apr; 47(2):253-63. PubMed ID: 18157543
[TBL] [Abstract][Full Text] [Related]
27. High-energy gamma rays in Hiroshima and Nagasaki: implications for risk and WR.
Straume T
Health Phys; 1995 Dec; 69(6):954-6. PubMed ID: 7493812
[TBL] [Abstract][Full Text] [Related]
28. RELATIVE BIOLOGICAL EFFECTIVENESS OF NEUTRONS DERIVED FROM THE EXCESS RELATIVE RISK MODEL WITH THE ATOMIC BOMB SURVIVORS DATA MANAGED BY HIROSHIMA UNIVERSITY.
Satoh K; Yasuda H; Kawakami H; Tashiro S
Radiat Prot Dosimetry; 2018 Aug; 180(1-4):346-350. PubMed ID: 29036656
[TBL] [Abstract][Full Text] [Related]
29. Solid cancer risk coefficient for fast neutrons in terms of effective dose.
Kellerer AM; Walsh L
Radiat Res; 2002 Jul; 158(1):61-8. PubMed ID: 12071804
[TBL] [Abstract][Full Text] [Related]
30. Current risk estimates based on the A-bomb survivors data - a discussion in terms of the ICRP recommendations on the neutron weighting factor.
Rühm W; Walsh L
Radiat Prot Dosimetry; 2007; 126(1-4):423-31. PubMed ID: 17533156
[TBL] [Abstract][Full Text] [Related]
31. DS02 fluence spectra for neutrons and gamma rays at Hiroshima and Nagasaki with fluence-to-kerma coefficients and transmission factors for sample measurements.
Egbert SD; Kerr GD; Cullings HM
Radiat Environ Biophys; 2007 Nov; 46(4):311-25. PubMed ID: 17643260
[TBL] [Abstract][Full Text] [Related]
32. Thermoluminescence dosimetry of gamma rays using ceramic samples from Hiroshima and Nagasaki: a comparison with DS86 estimates.
Nagatomo T; Ichikawa Y; Hoshi M
J Radiat Res; 1991 Mar; 32 Suppl():48-57. PubMed ID: 1762131
[TBL] [Abstract][Full Text] [Related]
33. The effect of changes in dosimetry on cancer mortality risk estimates in the atomic bomb survivors.
Preston DL; Pierce DA
Radiat Res; 1988 Jun; 114(3):437-66. PubMed ID: 3375435
[TBL] [Abstract][Full Text] [Related]
34. Risk estimates for radiation-induced cancer--the epidemiological evidence.
Kellerer AM
Radiat Environ Biophys; 2000 Mar; 39(1):17-24. PubMed ID: 10789891
[TBL] [Abstract][Full Text] [Related]
35. The F value for chromosome aberrations in atomic bomb survivors does not provide evidence for a primary contribution of neutrons to the dose in Hiroshima.
Kodama Y; Ohtaki K; Awa AA; Nakano M; Itoh M; Nakamura N
Radiat Res; 1999 Nov; 152(5):558-62. PubMed ID: 10521934
[TBL] [Abstract][Full Text] [Related]
36. (41)Ca in Tooth Enamel. Part II: A means for retrospective biological neutron dosimetry in atomic bomb survivors.
Rühm W; Wallner A; Cullings H; Egbert SD; El-Faramawy N; Faestermann T; Kaul D; Knie K; Korschinek G; Nakamura N; Roberts J; Rugel G
Radiat Res; 2010 Aug; 174(2):146-54. PubMed ID: 20681781
[TBL] [Abstract][Full Text] [Related]
37. Corrections in the atomic bomb data to examine low dose risk.
Baker GS; Hoel DG
Health Phys; 2003 Dec; 85(6):709-20. PubMed ID: 14626322
[TBL] [Abstract][Full Text] [Related]
38. The risk of non-melanoma skin cancer incidence in the Japanese atomic bomb survivors.
Little MP; Charles MW
Int J Radiat Biol; 1997 May; 71(5):589-602. PubMed ID: 9191904
[TBL] [Abstract][Full Text] [Related]
39. Analysis of the DS86 atomic bomb radiation dosimetry methods using data on severe epilation.
Stram DO; Mizuno S
Radiat Res; 1989 Jan; 117(1):93-113. PubMed ID: 2913611
[TBL] [Abstract][Full Text] [Related]
40. Cancer incidence risks above and below 1 Gy for radiation protection in space.
Hafner L; Walsh L; Schneider U
Life Sci Space Res (Amst); 2021 Feb; 28():41-56. PubMed ID: 33612179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
